You are here

  • Home
  • Archive
  • Volume 14, Issue 7
  • Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)

Citation Tools

Article menu

Download PDFPDF

Cardiovascular medicine
Protocol
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wang Y, Xu J, Ma L, et al
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)
BMJ Open 2024;14:e083730. doi: 10.1136/bmjopen-2023-083730